Ulcerative colitis is a chronic inflammatory bowel disease that can cause various symptoms, including ocular manifestations such as anterior uveitis. A biopsy of affected tissue is crucial in diagnosing ulcerative colitis and distinguishing it from other similar conditions, particularly Crohn’s disease. The characteristic microscopic features of ulcerative colitis include crypt abscesses and pseudopolyps. Partial villous atrophy is not typically associated with ulcerative colitis but may be seen in tropical sprue. Crypt hyperplasia and complete villous atrophy are more commonly seen in coeliac disease. Non-caseating granulomas and transmural inflammation are typical histological features of Crohn’s disease, which is the primary differential diagnosis for ulcerative colitis.

Inflammatory bowel disease (IBD) is a condition that includes two main types: Crohn’s disease and ulcerative colitis. Although they share many similarities in terms of symptoms, diagnosis, and treatment, there are some key differences between the two. Crohn’s disease is characterized by non-bloody diarrhea, weight loss, upper gastrointestinal symptoms, mouth ulcers, perianal disease, and a palpable abdominal mass in the right iliac fossa. On the other hand, ulcerative colitis is characterized by bloody diarrhea, abdominal pain in the left lower quadrant, tenesmus, gallstones, and primary sclerosing cholangitis. Complications of Crohn’s disease include obstruction, fistula, and colorectal cancer, while ulcerative colitis has a higher risk of colorectal cancer than Crohn’s disease. Pathologically, Crohn’s disease lesions can be seen anywhere from the mouth to anus, while ulcerative colitis inflammation always starts at the rectum and never spreads beyond the ileocaecal valve. Endoscopy and radiology can help diagnose and differentiate between the two types of IBD.

Gastric cancer is a relatively uncommon type of cancer, accounting for only 2% of all cancer diagnoses in developed countries. It is more prevalent in older individuals, with half of patients being over the age of 75, and is more common in males than females. Several risk factors have been identified, including Helicobacter pylori infection, atrophic gastritis, certain dietary habits, smoking, and blood group. Symptoms of gastric cancer can include abdominal pain, weight loss, nausea, vomiting, and dysphagia. In some cases, lymphatic spread may result in the appearance of nodules in the left supraclavicular lymph node or periumbilical area. Diagnosis is typically made through oesophago-gastro-duodenoscopy with biopsy, and staging is done using CT. Treatment options depend on the extent and location of the cancer and may include endoscopic mucosal resection, partial or total gastrectomy, and chemotherapy.

The recommended treatment for Clostridium difficile infections is antibiotics, with oral vancomycin being the first line option. IV metronidazole is only used in severe cases and in combination with oral vancomycin. Bezlotoxumab, a monoclonal antibody, may be used to prevent recurrence but is not currently considered cost-effective. Oral clarithromycin is not the preferred antibiotic for this type of infection. Conservative treatment with IV fluids and antipyretics is not appropriate and antibiotics should be administered.

Clostridium difficile is a type of bacteria that is commonly found in hospitals. It produces a toxin that can damage the intestines and cause a condition called pseudomembranous colitis. This bacteria usually develops when the normal gut flora is disrupted by broad-spectrum antibiotics, with second and third generation cephalosporins being the leading cause. Other risk factors include the use of proton pump inhibitors. Symptoms of C. difficile infection include diarrhea, abdominal pain, and a raised white blood cell count. The severity of the infection can be determined using the Public Health England severity scale.

To diagnose C. difficile infection, a stool sample is tested for the presence of the C. difficile toxin. Treatment involves reviewing current antibiotic therapy and stopping antibiotics if possible. For a first episode of infection, oral vancomycin is the first-line therapy for 10 days, followed by oral fidaxomicin as second-line therapy and oral vancomycin with or without IV metronidazole as third-line therapy. Recurrent infections may require different treatment options, such as oral fidaxomicin within 12 weeks of symptom resolution or oral vancomycin or fidaxomicin after 12 weeks of symptom resolution. In life-threatening cases, oral vancomycin and IV metronidazole may be used, and surgery may be considered with specialist advice. Other therapies, such as bezlotoxumab and fecal microbiota transplant, may also be considered for preventing recurrences in certain cases.

At the superior part of the pancreas, the gastroduodenal artery splits into the pancreaticoduodenal and gastro-epiploic arteries.

Anatomy of the Pancreas

The pancreas is located behind the stomach and is a retroperitoneal organ. It can be accessed surgically by dividing the peritoneal reflection that connects the greater omentum to the transverse colon. The pancreatic head is situated in the curvature of the duodenum, while its tail is close to the hilum of the spleen. The pancreas has various relations with other organs, such as the inferior vena cava, common bile duct, renal veins, superior mesenteric vein and artery, crus of diaphragm, psoas muscle, adrenal gland, kidney, aorta, pylorus, gastroduodenal artery, and splenic hilum.

The arterial supply of the pancreas is through the pancreaticoduodenal artery for the head and the splenic artery for the rest of the organ. The venous drainage for the head is through the superior mesenteric vein, while the body and tail are drained by the splenic vein. The ampulla of Vater is an important landmark that marks the transition from foregut to midgut and is located halfway along the second part of the duodenum. Overall, understanding the anatomy of the pancreas is crucial for surgical procedures and diagnosing pancreatic diseases.

To induce remission of Crohn’s disease, glucocorticoids (whether oral, topical or intravenous) are typically the first line of treatment. 5-ASA drugs are considered a second option for inducing remission of IBD. Azathioprine is more commonly used for maintaining remission. Steroids are specifically used to induce remission of Crohn’s disease. Infliximab is particularly effective for treating refractory disease and fistulating Crohn’s.

Crohn’s disease is a type of inflammatory bowel disease that can affect any part of the digestive tract. The National Institute for Health and Care Excellence (NICE) has published guidelines for managing this condition. Patients are advised to quit smoking, as it can worsen Crohn’s disease. While some studies suggest that NSAIDs and the combined oral contraceptive pill may increase the risk of relapse, the evidence is not conclusive.

To induce remission, glucocorticoids are typically used, but budesonide may be an alternative for some patients. Enteral feeding with an elemental diet may also be used, especially in young children or when there are concerns about steroid side effects. Second-line options include 5-ASA drugs, such as mesalazine, and add-on medications like azathioprine or mercaptopurine. Infliximab is useful for refractory disease and fistulating Crohn’s, and metronidazole is often used for isolated peri-anal disease.

Maintaining remission involves stopping smoking and using azathioprine or mercaptopurine as first-line options. Methotrexate is a second-line option. Surgery is eventually required for around 80% of patients with Crohn’s disease, depending on the location and severity of the disease. Complications of Crohn’s disease include small bowel cancer, colorectal cancer, and osteoporosis. Before offering azathioprine or mercaptopurine, it is important to assess thiopurine methyltransferase (TPMT) activity.

The classic triad for achalasia includes loss of peristalsis, increased lower sphincter tone, and inadequate relaxation of the lower sphincter, which is evident on manometry. Dysphagia for both solid and liquid is also a common symptom of achalasia.

Unlike achalasia, Barrett’s esophagus does not show any changes on manometry. However, it can be identified through the presence of intestinal metaplasia on endoscopy.

Diffuse esophageal spasm is a motility disorder that does not affect lower esophageal sphincter pressure and relaxation during swallowing. Instead, manometry reveals repetitive high amplitude contractions.

Hiatus hernia is typically associated with gastroesophageal reflux disease and does not show any abnormal findings on manometry.

Understanding Dysphagia and its Causes

Dysphagia, or difficulty in swallowing, can be caused by various conditions affecting the oesophagus, including cancer, oesophagitis, candidiasis, achalasia, pharyngeal pouch, systemic sclerosis, myasthenia gravis, and globus hystericus. These conditions have distinct features that can help in their diagnosis, such as weight loss and anorexia in oesophageal cancer, heartburn in oesophagitis, dysphagia of both liquids and solids in achalasia, and anxiety in globus hystericus. Dysphagia can also be classified as extrinsic, intrinsic, or neurological, depending on the underlying cause.

To diagnose dysphagia, patients usually undergo an upper GI endoscopy, a full blood count, and fluoroscopic swallowing studies. Additional tests, such as ambulatory oesophageal pH and manometry studies, may be needed for specific conditions. It’s important to note that new-onset dysphagia is a red flag symptom that requires urgent endoscopy, regardless of age or other symptoms. By understanding the causes and features of dysphagia, healthcare professionals can provide timely and appropriate management for their patients.

The inferior mesenteric artery is responsible for supplying blood to the hindgut, which includes the distal third of the colon and the rectum superior to the pectinate line. In this case, the patient’s sudden onset of severe abdominal pain and history of atrial fibrillation suggest acute mesenteric ischemia, with the affected artery being the inferior mesenteric artery. Therefore, if a thrombus were to block this artery, the distal third of the colon and superior rectum would experience ischaemic changes. It is important to note that the ascending colon, caecum, ileum, appendix, greater omentum, and stomach are supplied by different arteries and would not be affected by a thrombus in the inferior mesenteric artery.

The Inferior Mesenteric Artery: Supplying the Hindgut

The inferior mesenteric artery (IMA) is responsible for supplying the embryonic hindgut with blood. It originates just above the aortic bifurcation, at the level of L3, and passes across the front of the aorta before settling on its left side. At the point where the left common iliac artery is located, the IMA becomes the superior rectal artery.

The hindgut, which includes the distal third of the colon and the rectum above the pectinate line, is supplied by the IMA. The left colic artery is one of the branches that emerges from the IMA near its origin. Up to three sigmoid arteries may also exit the IMA to supply the sigmoid colon further down the line.

Overall, the IMA plays a crucial role in ensuring that the hindgut receives the blood supply it needs to function properly. Its branches help to ensure that the colon and rectum are well-nourished and able to carry out their important digestive functions.

If the ureters are damaged during a caesarean section, it can cause fluid to accumulate in the retroperitoneal area. This can lead to pain and inflammation, which may present as fever and a rapid heartbeat. Ovarian thrombus is a rare complication that can occur after a caesarean section. CT scans can show filling defects and an increased diameter in the affected vein. The pyloric antrum is located near the bottom of the stomach, close to the pyloric sphincter. Since the stomach is an intraperitoneal organ in the left upper quadrant, it is unlikely to be lacerated during a caesarean section. Any damage to the stomach would not result in retroperitoneal fluid accumulation.

The retroperitoneal structures are those that are located behind the peritoneum, which is the membrane that lines the abdominal cavity. These structures include the duodenum (2nd, 3rd, and 4th parts), ascending and descending colon, kidneys, ureters, aorta, and inferior vena cava. They are situated in the back of the abdominal cavity, close to the spine. In contrast, intraperitoneal structures are those that are located within the peritoneal cavity, such as the stomach, duodenum (1st part), jejunum, ileum, transverse colon, and sigmoid colon. It is important to note that the retroperitoneal structures are not well demonstrated in the diagram as the posterior aspect has been removed, but they are still significant in terms of their location and function.

Individuals with Gilbert’s syndrome exhibit a decrease in the amount of UDP glucuronosyltransferase, an enzyme responsible for conjugating bilirubin in the liver. This deficiency leads to an accumulation of unconjugated bilirubin, which cannot be eliminated through urine, resulting in jaundice. Although symptoms may arise during periods of stress, the condition is generally not clinically significant.

HMG-CoA reductase is an enzyme involved in cholesterol synthesis, while lipoprotein lipase plays a central role in lipid metabolism and is associated with various conditions such as hypertriglyceridemia. G6PD deficiency, on the other hand, affects the pentose phosphate pathway by reducing the production of NADPH.

Gilbert’s syndrome is a genetic disorder that affects the way bilirubin is processed in the body. It is caused by a deficiency of UDP glucuronosyltransferase, which leads to unconjugated hyperbilirubinemia. This means that bilirubin is not properly broken down and eliminated from the body, resulting in jaundice. However, jaundice may only be visible during certain conditions such as fasting, exercise, or illness. The prevalence of Gilbert’s syndrome is around 1-2% in the general population.

To diagnose Gilbert’s syndrome, doctors may look for a rise in bilirubin levels after prolonged fasting or the administration of IV nicotinic acid. However, treatment is not necessary for this condition. While the exact mode of inheritance is still debated, it is known to be an autosomal recessive disorder.

Wilson’s disease causes elevated copper levels in the body, leading to deposits in various organs, with the basal ganglia in the brain being the most commonly affected. Damage to this structure results in symptoms. Broca’s area in the frontal lobe is involved in language production and is commonly affected in stroke. The midbrain is involved in consciousness and movement, while the motor cortex is involved in planning and executing movement. The ventricles are fluid-filled spaces involved in cerebrospinal fluid movement and formation.

Understanding Wilson’s Disease

Wilson’s disease is a genetic disorder that causes excessive copper accumulation in the tissues due to metabolic abnormalities. It is an autosomal recessive disorder caused by a defect in the ATP7B gene located on chromosome 13. Symptoms usually appear between the ages of 10 to 25 years, with children presenting with liver disease and young adults with neurological disease.

The disease is characterised by excessive copper deposition in the tissues, particularly in the brain, liver, and cornea. This can lead to a range of symptoms, including hepatitis, cirrhosis, basal ganglia degeneration, speech and behavioural problems, asterixis, chorea, dementia, parkinsonism, Kayser-Fleischer rings, renal tubular acidosis, haemolysis, and blue nails.

To diagnose Wilson’s disease, doctors may perform a slit lamp examination for Kayser-Fleischer rings, measure serum ceruloplasmin and total serum copper (which is often reduced), and check for increased 24-hour urinary copper excretion. Genetic analysis of the ATP7B gene can confirm the diagnosis.

Treatment for Wilson’s disease typically involves chelating agents such as penicillamine or trientine hydrochloride, which help to remove excess copper from the body. Tetrathiomolybdate is a newer agent that is currently under investigation. With proper management, individuals with Wilson’s disease can lead normal lives.